The NSCLC RET fusion-positive patients presented similar, however, less common and more various, grade 3/4 treatment-related AEs than MTC patients: hypertension (9%), increased ALT (9%), increased AST (6%), prolonged QT (2%), diarrhea, rash, vomiting, and pyrexia (1% respectively). The gene discussed is GPT; the disease is medullary thyroid gland carcinoma.